Citing "preclinical and preliminary clinical evidence," Novartis, in a press statement, said Jakavi "could reduce the number of patients requiring intensive care and mechanical ventilation."Novartis joins Roche, Sanofi, and Regeneron, which are all testing out drugs previously approved to treat arthritis to see if they might also work on Covid-19 patients suffering from severe immune system overreactions.